Thrombosis and sickle cell disease

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 3, 2011, Pages 226-236

  De Franceschi, Lucia ^a   Cappellini, Maria Domenica ^b   Olivieri, Oliviero ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

dense red cells; Hypercoagulability; inflammation; neutrophils; vascular endothelial dysfunction

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACENOCOUMAROL; ACETYLSALICYLIC ACID; D DIMER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; FIBRINOLYTIC AGENT; HEPARIN; HUMAN PLATELET ALLOANTIGEN; INTERLEUKIN 4; LYMPHOCYTE ANTIGEN; NITRIC OXIDE; OMEGA 3 FATTY ACID; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; PROTEIN S; THROMBOSPONDIN; TINZAPARIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; WARFARIN;

ARTICLE; BIOAVAILABILITY; BLEEDING; BLOOD CLOTTING; BLOOD GROUP LUTHERAN SYSTEM; BLOOD LEVEL; BLOOD VESSEL OCCLUSION; CARDIOVASCULAR RISK; CYTOKINE PRODUCTION; DNA MODIFICATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; FIBRINOLYSIS; GENE TARGETING; GENETIC POLYMORPHISM; HEMOLYSIS; HYPERCOAGULABILITY; INFLAMMATION; METABOLISM; MOYAMOYA DISEASE; NEUTROPHIL CHEMOTAXIS; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN MULTIMERIZATION; PSEUDOXANTHOMA ELASTICUM; RISK ASSESSMENT; SICKLE CELL ANEMIA; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; VASCULAR DISEASE; VASCULAR ENDOTHELIAL DYSFUNCTION;

ANEMIA, SICKLE CELL; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD PLATELETS; ENDOTHELIUM, VASCULAR; ERYTHROCYTES; ERYTHROCYTES, ABNORMAL; HEMOGLOBIN, SICKLE; HUMANS; INFLAMMATION; LEUKOCYTES; NITRIC OXIDE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS;

EID: 79953662398     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1273087     Document Type: Article

References (146)

1. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008 86 6 480-487 (Pubitemid 351821761)
2. Modell B, Darlison M, Birgens H et al. Epidemiology of haemoglobin disorders in Europe: an overview. Scand J Clin Lab Invest 2007 67 1 39-69
3. Weatherall D J. The global problem of genetic disease. Ann Hum Biol 2005 32 2 117-122 (Pubitemid 40995611)
4. Weatherall D J., Clegg J B. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ 2001 79 8 704-712 (Pubitemid 32776838)
5. Eaton W A., Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem 1990 40 63-279 (Pubitemid 20235566)
6. Steinberg M H. Management of sickle cell disease. N Engl J Med 1999 340 13 1021-1030 (Pubitemid 29157635)
7. Ballas S K., Smith E D. Red blood cell changes during the evolution of the sickle cell painful crisis. Blood 1992 79 8 2154-2163
8. Solovey A A., Solovey A N., Harkness J, Hebbel R P. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood 2001 97 7 1937-1941 (Pubitemid 32239070)
9. Gayen Betal S, Setty B N. Phosphatidylserine-positive erythrocytes bind to immobilized and soluble thrombospondin-1 via its heparin-binding domain. Transl Res 2008 152 4 165-177
10. Setty B N., Betal S G., Zhang J, Stuart M J. Heme induces endothelial tissue factor expression: potential role in hemostatic activation in patients with hemolytic anemia. J Thromb Haemost 2008 6 12 2202-2209
11. Setty B N., Rao A K., Stuart M J. Thrombophilia in sickle cell disease: the red cell connection. Blood 2001 98 12 3228-3233
12. Rosenbaum C, Peace D, Rich E, Van Besien K. Granulocyte colony-stimulating factor-based stem cell mobilization in patients with sickle cell disease. Biol Blood Marrow Transplant 2008 14 6 719-723 (Pubitemid 351664057)
13. Ataga K I., Cappellini M D., Rachmilewitz E A. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol 2007 139 1 3-13 (Pubitemid 47389919)
14. Ataga K I., Orringer E P. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 2003 115 9 721-728 (Pubitemid 38032666)
15. Cappellini M D. Coagulation in the pathophysiology of hemolytic anemias [review]. Hematology Am Soc Hematol Educ Program 2007 74-78
16. Morris C R. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program 2008 177-185
17. Adam S S., Key N S., Greenberg C S. D-dimer antigen: current concepts and future prospects. Blood 2009 113 13 2878-2887
18. Archer D R., Stiles J K., Newman G W. et al. C-reactive protein and interleukin-6 are decreased in transgenic sickle cell mice fed a high protein diet. J Nutr 2008 138 6 1148-1152 (Pubitemid 351769143)
19. Ou J, Ou Z, Jones D W. et al. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 2003 107 18 2337-2341 (Pubitemid 36578505)
20. Lanaro C, Franco-Penteado C F., Albuqueque D M., Saad S T., Conran N, Costa F F. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J Leukoc Biol 2009 85 2 235-242
21. Austin H, Key N S., Benson J M. et al. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood 2007 110 3 908-912 (Pubitemid 47267428)
22. Stein P D., Beemath A, Meyers F A., Skaf E, Olson R E. Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. Am J Med 2006 119 10 897 e7-e11
23. Verduzco L A., Nathan D G. Sickle cell disease and stroke. Blood 2009 114 25 5117-5125
24. James A H., Jamison M G., Brancazio L R., Myers E R. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006 194 5 1311-1315
25. Prengler M, Pavlakis S G., Prohovnik I, Adams R J. Sickle cell disease: the neurological complications. Ann Neurol 2002 51 5 543-552
26. Adedeji M O., Cespedes J, Allen K, Subramony C, Hughson M D. Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med 2001 125 11 1436-1441 (Pubitemid 33070181)
27. Haque A K., Gokhale S, Rampy B A., Adegboyega P, Duarte A, Saldana M J. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol 2002 33 10 1037-1043 (Pubitemid 35215849)
28. Peters M, Plaat B E., ten Cate H, Wolters H J., Weening R S., Brandjes D P. Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost 1994 71 2 169-172 (Pubitemid 24047320)
29. Tomer A, Kasey S, Connor W E., Clark S, Harker L A., Eckman J R. Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids. Thromb Haemost 2001 85 6 966-974 (Pubitemid 32573744)
30. Leslie J, Langler D, Serjeant G R., Serjeant B E., Desai P, Gordon Y B. Coagulation changes during the steady state in homozygous sickle-cell disease in Jamaica. Br J Haematol 1975 30 2 159-166
31. Rickles F R., O'Leary D S. Role of coagulation system in pathophysiology of sickle cell disease. Arch Intern Med 1974 133 4 635-641
32. Stuart M J., Setty B N. Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology. Pediatr Pathol Mol Med 2001 20 1 27-46 (Pubitemid 32168001)
33. Green D, Scott J P. Is sickle cell crisis a thrombotic event? Am J Hematol 1986 23 4 317-321 (Pubitemid 17191519)
34. Francis R B. Jr. Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis 1989 19 2 105-111 (Pubitemid 19095129)
35. Richardson S G., Matthews K B., Stuart J, Geddes A M., Wilcox R M. Serial changes in coagulation and viscosity during sickle-cell crisis. Br J Haematol 1979 41 1 95-103 (Pubitemid 9073672)
36. Tomer A, Harker L A., Kasey S, Eckman J R. Thrombogenesis in sickle cell disease. J Lab Clin Med 2001 137 6 398-407 (Pubitemid 32473618)
37. Kurantsin-Mills J, Ofosu F A., Safa T K., Siegel R S., Lessin L S. Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients. Br J Haematol 1992 81 4 539-544
38. Westerman M P., Green D, Gilman-Sachs A et al. Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med 1999 134 4 352-362 (Pubitemid 29490154)
39. Hagger D, Wolff S, Owen J, Samson D. Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls. Blood Coagul Fibrinolysis 1995 6 2 93-99
40. Branch D W., Rodgers G M. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol 1993 168 1 Pt 1 206-210 (Pubitemid 23047642)
41. Ataga K I., Moore C G., Hillery C A. et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica 2008 93 1 20-26 (Pubitemid 351156147)
42. van Beers E J., Spronk H M., Ten Cate H et al, CURAMA study Group. No association of the hypercoagulable state with sickle cell disease related pulmonary hypertension. Haematologica 2008 93 5 e42-e44 (Pubitemid 351669332)
43. Shet A S., Aras O, Gupta K et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003 102 7 2678-2683 (Pubitemid 37193612)
44. van Beers E J., Schaap M C., Berckmans R J. et al, CURAMA study group. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica 2009 94 11 1513-1519
45. Tam D A. Protein C and protein S activity in sickle cell disease and stroke. J Child Neurol 1997 12 1 19-21
46. el-Hazmi M A., Warsy A S., Bahakim H. Blood proteins C and S in sickle cell disease. Acta Haematol 1993 90 3 114-119 (Pubitemid 24041984)
47. Karayalcin G, Lanzkowsky P. Plasma protein C levels in children with sickle cell disease. Am J Pediatr Hematol Oncol 1989 11 3 320-323 (Pubitemid 19213453)
48. Kuypers F A., Larkin S K., Emeis J J., Allison A C. Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity. Thromb Haemost 2007 97 3 478-486 (Pubitemid 46437812)
49. Lane P A., O'Connell J L., Marlar R A. Erythrocyte membrane vesicles and irreversibly sickled cells bind protein S. Am J Hematol 1994 47 4 295-300 (Pubitemid 24372284)
50. Nsiri B, Gritli N, Bayoudh F, Messaoud T, Fattoum S, Machghoul S. Abnormalities of coagulation and fibrinolysis in homozygous sickle cell disease. Hematol Cell Ther 1996 38 3 279-284 (Pubitemid 26291422)
51. Nsiri B, Gritli N, Mazigh C, Ghazouani E, Fattoum S, Machghoul S. Fibrinolytic response to venous occlusion in patients with homozygous sickle cell disease. Hematol Cell Ther 1997 39 5 229-232 (Pubitemid 27483732)
52. Yamamoto K, Saito H. A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders. Int J Hematol 1998 68 4 371-385 (Pubitemid 28559115)
53. Key N S., Slungaard A, Dandelet L et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998 91 11 4216-4223 (Pubitemid 28261985)
54. Solovey A, Gui L, Key N S., Hebbel R P. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest 1998 101 9 1899-1904 (Pubitemid 28226109)
55. Andrade F L., Annichino-Bizzacchi J M., Saad S T., Costa F F., Arruda V R. Prothrombin mutant, factor V Leiden, and thermolabile variant of methylenetetrahydrofolate reductase among patients with sickle cell disease in Brazil. Am J Hematol 1998 59 1 46-50 (Pubitemid 28395006)
56. Kahn M J., Scher C, Rozans M, Michaels R K., Leissinger C, Krause J. Factor V Leiden is not responsible for stroke in patients with sickling disorders and is uncommon in African Americans with sickle cell disease. Am J Hematol 1997 54 1 12-15 (Pubitemid 27013897)
57. Cumming A M., Olujohungbe A, Keeney S, Singh H, Hay C R., Serjeant G R. The methylenetetrahydrofolate reductase gene C677T polymorphism in patients with homozygous sickle cell disease and stroke. Br J Haematol 1999 107 3 569-571
58. Rees D C., Chapman N H., Webster M T., Guerreiro J F., Rochette J, Clegg J B. Born to clot: the European burden. Br J Haematol 1999 105 2 564-566 (Pubitemid 29232189)
59. Rahimi Z, Vaisi-Raygani A, Nagel R L., Muniz A. Thrombophilic mutations among Southern Iranian patients with sickle cell disease: high prevalence of factor V Leiden. J Thromb Thrombolysis 2008 25 3 288-292 (Pubitemid 351772733)
60. Isma'eel H, Arnaout M S., Shamseddeen W et al. Screening for inherited thrombophilia might be warranted among Eastern Mediterranean sickle-beta-0 thalassemia patients. J Thromb Thrombolysis 2006 22 2 121-123 (Pubitemid 44473562)
61. Fawaz N A., Bashawery L, Al-Sheikh I, Qatari A, Al-Othman S S., Almawi W Y. Factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations among patients with sickle cell disease in Eastern Saudi Arabia. Am J Hematol 2004 76 3 307-309 (Pubitemid 38828860)
62. Zimmerman S A., Ware R E. Inherited DNA mutations contributing to thrombotic complications in patients with sickle cell disease. Am J Hematol 1998 59 4 267-272 (Pubitemid 28543614)
63. Adekile A D., Kutlar F, Haider M Z., Kutlar A. Frequency of the 677 C> T mutation of the methylenetetrahydrofolate reductase gene among Kuwaiti sickle cell disease patients. Am J Hematol 2001 66 4 263-266 (Pubitemid 32210294)
64. Foulon I, Bachir D, Galacteros F, Maclouf J. Increased in vivo production of thromboxane in patients with sickle cell disease is accompanied by an impairment of platelet functions to the thromboxane A2 agonist U46619. Arterioscler Thromb 1993 13 3 421-426 (Pubitemid 23075632)
65. Browne P V., Mosher D F., Steinberg M H., Hebbel R P. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol 1996 51 4 296-301 (Pubitemid 26116369)
66. Kenny M W., George A J., Stuart J. Platelet hyperactivity in sickle-cell disease: a consequence of hyposplenism. J Clin Pathol 1980 33 7 622-625 (Pubitemid 10036711)
67. Westwick J, Watson-Williams E J., Krishnamurthi S et al. Platelet activation during steady state sickle cell disease. J Med 1983 14 1 17-36 (Pubitemid 13003057)
68. Winichagoon P, Fucharoen S, Wasi P. Increased circulating platelet aggregates in thalassaemia. Southeast Asian J Trop Med Public Health 1981 12 4 556-560 (Pubitemid 12084732)
69. Wun T, Paglieroni T, Rangaswami A et al. Platelet activation in patients with sickle cell disease. Br J Haematol 1998 100 4 741-749 (Pubitemid 28126109)
70. Famodu A A., Oduwa D. Platelet count and platelet factor 3 (PF-3) availability in sickle cell disease. Br J Biomed Sci 1995 52 4 323-324 (Pubitemid 26007490)
71. Lee S P., Ataga K I., Orringer E P., Phillips D R., Parise L V. Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol 2006 26 7 1626-1631 (Pubitemid 44288993)
72. Villagra J, Shiva S, Hunter L A., Machado R F., Gladwin M T., Kato G J. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 2007 110 6 2166-2172 (Pubitemid 47443936)
73. Proença-Ferreira R, Franco-Penteado C F., Traina F, Saad S T., Costa F F., Conran N. Increased adhesive properties of platelets in sickle cell disease: roles for alphaIIb beta3-mediated ligand binding, diminished cAMP signalling and increased phosphodiesterase 3A activity. Br J Haematol 2010 149 2 280-288
74. Mehta P, Mehta J. Abnormalities of platelet aggregation in sickle cell disease. J Pediatr 1980 96 2 209-213 (Pubitemid 10129398)
75. Haut M J., Cowan D H., Harris J W. Platelet function and survival in sickle cell disease. J Lab Clin Med 1973 82 1 44-53
76. Buchanan G R., Holtkamp C A. Evidence against enhanced platelet activity in sickle cell anaemia. Br J Haematol 1983 54 4 595-603 (Pubitemid 13079075)
77. Kunicki T J. The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease. Arterioscler Thromb Vasc Biol 2002 22 1 14-20 (Pubitemid 34076226)
78. Deckmyn H, Ulrichts H, Van De Walle G, Vanhoorelbeke K. Platelet antigens and their function. Vox Sang 2004 87 Suppl 2 105-111
79. Bray P F. Platelet glycoprotein polymorphisms as risk factors for thrombosis. Curr Opin Hematol 2000 7 5 284-289 (Pubitemid 30637667)
80. Castro V, Alberto F L., Costa R N. et al. Polymorphism of the human platelet antigen-5 system is a risk factor for occlusive vascular complications in patients with sickle cell anemia. Vox Sang 2004 87 2 118-123 (Pubitemid 39265460)
81. Al-Subaie A M., Fawaz N A., Mahdi N et al. Human platelet alloantigens (HPA) 1, HPA2, HPA3, HPA4, and HPA5 polymorphisms in sickle cell anemia patients with vaso-occlusive crisis. Eur J Haematol 2009 83 6 579-585
82. Solovey A, Gui L, Ramakrishnan S, Steinberg M H., Hebbel R P. Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells. Blood 1999 93 11 3824-3830 (Pubitemid 29249829)
83. Ortiz A. Circulating endothelial cells in sickle cell anemia. N Engl J Med 1998 338 16 1162 author reply 1162-1163
84. Parise L V., Telen M J. Erythrocyte adhesion in sickle cell disease. Curr Hematol Rep 2003 2 2 102-108
85. De Franceschi L, Corrocher R. Established and experimental treatments for sickle cell disease. Haematologica 2004 89 3 348-356 (Pubitemid 38788421)
86. Kaul D K., Tsai H M., Liu X D., Nakada M T., Nagel R L., Coller B S. Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood 2000 95 2 368-374 (Pubitemid 30041643)
87. Barabino G A., Liu X D., Ewenstein B M., Kaul D K. Anionic polysaccharides inhibit adhesion of sickle erythrocytes to the vascular endothelium and result in improved hemodynamic behavior. Blood 1999 93 4 1422-1429 (Pubitemid 29076159)
88. Hines P C., Zen Q, Burney S N. et al. Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. Blood 2003 101 8 3281-3287 (Pubitemid 36858025)
89. Murphy M M., Zayed M A., Evans A et al. Role of Rap1 in promoting sickle red blood cell adhesion to laminin via BCAM/LU. Blood 2005 105 8 3322-3329
90. Zennadi R, Hines P C., De Castro L M., Cartron J P., Parise L V., Telen M J. Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions. Blood 2004 104 12 3774-3781 (Pubitemid 39564457)
91. Zennadi R, De Castro L, Eyler C, Xu K, Ko M, Telen M J. Role and regulation of sickle red cell interactions with other cells: ICAM-4 and other adhesion receptors. Transfus Clin Biol 2008 15 1-2 23-28
92. Kaul D K., Liu X D., Zhang X et al. Peptides based on alphaV-binding domains of erythrocyte ICAM-4 inhibit sickle red cell-endothelial interactions and vaso-occlusion in the microcirculation. Am J Physiol Cell Physiol 2006 291 5 C922-C930 (Pubitemid 44771811)
93. Mankelow T J., Spring F A., Parsons S F. et al. Identification of critical amino-acid residues on the erythroid intercellular adhesion molecule-4 (ICAM-4) mediating adhesion to alpha V integrins. Blood 2004 103 4 1503-1508 (Pubitemid 38168669)
94. Sabina R L., Wandersee N J., Hillery C A. Ca2 + -CaM activation of AMP deaminase contributes to adenine nucleotide dysregulation and phosphatidylserine externalization in human sickle erythrocytes. Br J Haematol 2009 144 3 434-445
95. Hebbel R P. Adhesion of sickle red cells to endothelium: myths and future directions. Transfus Clin Biol 2008 15 1-2 14-18
96. Kuypers F A., Styles L A. The role of secretory phospholipase A2 in acute chest syndrome. Cell Mol Biol (Noisy-le-grand) 2004 50 1 87-94
97. Kuypers F A., de Jong K. The role of phosphatidylserine in recognition and removal of erythrocytes. Cell Mol Biol (Noisy-le-grand) 2004 50 2 147-158
98. Schnog J J., Hovinga J A., Krieg S et al, CURAMA Study Group. ADAMTS13 activity in sickle cell disease. Am J Hematol 2006 81 7 492-498
99. Krishnan S, Siegel J, Pullen G Jr, Hevelow M, Dampier C, Stuart M. Increased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemia. Thromb Res 2008 122 4 455-458
100. Roberts D D., Williams S B., Gralnick H R., Ginsburg V. von Willebrand factor binds specifically to sulfated glycolipids. J Biol Chem 1986 261 7 3306-3309 (Pubitemid 17204945)
101. Kaul D K., Nagel R L., Chen D, Tsai H M. Sickle erythrocyte-endothelial interactions in microcirculation: the role of von Willebrand factor and implications for vasoocclusion. Blood 1993 81 9 2429-2438 (Pubitemid 23127081)
102. Tsai H M. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med 2006 57 419-436
103. Sadler J E. A new name in thrombosis, ADAMTS13. Proc Natl Acad Sci U S A 2002 99 18 11552-11554 (Pubitemid 34994433)
104. Feys H B., Anderson P J., Vanhoorelbeke K, Majerus E M., Sadler J E. Multi-step binding of ADAMTS-13 to von Willebrand factor. J Thromb Haemost 2009 7 12 2088-2095
105. Turner N A., Nolasco L, Ruggeri Z M., Moake J L. Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage. Blood 2009 114 24 5102-5111
106. Studt J D., Hovinga J A., Antoine G et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 2005 105 2 542-544 (Pubitemid 40070733)
107. Zhou Z, Han H, Cruz M A., López J A., Dong J F., Guchhait P. Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost 2009 101 6 1070-1077
108. Taylor J G. VI, Tang D C., Savage S A. et al. Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood 2002 100 13 4303-4309 (Pubitemid 35429667)
109. Hoppe C, Klitz W, D'Harlingue K et al, Stroke Prevention Trial in Sickle Cell Anemia (STOP) Investigators. Confirmation of an association between the TNF(-308) promoter polymorphism and stroke risk in children with sickle cell anemia. Stroke 2007 38 8 2241-2246 (Pubitemid 47457562)
110. Chaar V, Tarer V, Etienne-Julan M, Diara J P., Elion J, Romana M. ET-1 and ecNOS gene polymorphisms and susceptibility to acute chest syndrome and painful vaso-occlusive crises in children with sickle cell anemia. Haematologica 2006 91 9 1277-1278 (Pubitemid 44408445)
111. Sharan K, Surrey S, Ballas S et al. Association of T-786C eNOS gene polymorphism with increased susceptibility to acute chest syndrome in females with sickle cell disease. Br J Haematol 2004 124 2 240-243 (Pubitemid 38122198)
112. Baldwin C, Nolan V G., Wyszynski D F. et al. Association of klotho, bone morphogenic protein 6, and annexin A2 polymorphisms with sickle cell osteonecrosis. Blood 2005 106 1 372-375 (Pubitemid 40967216)
113. Sebastiani P, Ramoni M F., Nolan V, Baldwin C T., Steinberg M H. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005 37 4 435-440
114. Nolan V G., Baldwin C, Ma Q et al. Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anaemia. Br J Haematol 2005 128 2 266-272
115. Nolan V G., Adewoye A, Baldwin C et al. Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol 2006 133 5 570-578
116. Elliott L, Ashley-Koch A E., De Castro L et al. Genetic polymorphisms associated with priapism in sickle cell disease. Br J Haematol 2007 137 3 262-267 (Pubitemid 46537636)
117. Graido-Gonzalez E, Doherty J C., Bergreen E W., Organ G, Telfer M, McMillen M A. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood 1998 92 7 2551-2555 (Pubitemid 28453000)
118. Natarajan M, Udden M M., McIntire L V. Adhesion of sickle red blood cells and damage to interleukin-1 beta stimulated endothelial cells under flow in vitro. Blood 1996 87 11 4845-4852 (Pubitemid 26162388)
119. Croizat H. Circulating cytokines in sickle cell patients during steady state. Br J Haematol 1994 87 3 592-597 (Pubitemid 24230028)
120. Francis R B. Jr, Haywood L J. Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. J Natl Med Assoc 1992 84 7 611-615
121. Hibbert J M., Hsu L L., Bhathena S J. et al. Proinflammatory cytokines and the hypermetabolism of children with sickle cell disease. Exp Biol Med (Maywood) 2005 230 1 68-74 (Pubitemid 40041074)
122. Conran N, Costa F F. Hemoglobin disorders and endothelial cell interactions. Clin Biochem 2009 42 18 1824-1838
123. Enenstein J, Milbauer L, Domingo E et al. Proinflammatory phenotype with imbalance of KLF2 and RelA: risk of childhood stroke with sickle cell anemia. Am J Hematol 2010 85 1 18-23
124. Fadlon E, Vordermeier S, Pearson T C. et al. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood 1998 91 1 266-274 (Pubitemid 28018754)
125. Canalli A A., Franco-Penteado C F., Saad S T., Conran N, Costa F F. Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation. Haematologica 2008 93 4 605-609 (Pubitemid 351536391)
126. Lum A F., Wun T, Staunton D, Simon S I. Inflammatory potential of neutrophils detected in sickle cell disease. Am J Hematol 2004 76 2 126-133 (Pubitemid 38702555)
127. Assis A, Conran N, Canalli A A., Lorand-Metze I, Saad S T., Costa F F. Effect of cytokines and chemokines on sickle neutrophil adhesion to fibronectin. Acta Haematol 2005 113 2 130-136 (Pubitemid 40522817)
128. Hidalgo A, Chang J, Jang J E., Peired A J., Chiang E Y., Frenette P S. Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. Nat Med 2009 15 4 384-391
129. Wallace K L., Marshall M A., Ramos S I. et al. NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines. Blood 2009 114 3 667-676
130. de Franceschi L, Baron A, Scarpa A et al. Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. Blood 2003 102 3 1087-1096 (Pubitemid 36917810)
131. Yang Y, Loscalzo J. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation 2000 101 18 2144-2148 (Pubitemid 30253041)
132. Kato G J., Martyr S, Blackwelder W C. et al. Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br J Haematol 2005 130 6 943-953 (Pubitemid 43899735)
133. Chaplin H Jr, Alkjaersig N, Fletcher A P., Michael J M., Joist J H. Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises. Thromb Haemost 1980 43 3 218-221 (Pubitemid 10044802)
134. Osamo N O., Photiades D P., Famodu A A. Therapeutic effect of aspirin in sickle cell anaemia. Acta Haematol 1981 66 2 102-107 (Pubitemid 11041813)
135. Greenberg J, Ohene-Frempong K, Halus J, Way C, Schwartz E. Trial of low doses of aspirin as prophylaxis in sickle cell disease. J Pediatr 1983 102 5 781-784 (Pubitemid 13089418)
136. Semple M J., Al-Hasani S F., Kioy P, Savidge G F. A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost 1984 51 3 303-306 (Pubitemid 14097879)
137. Cabannes R, Lonsdorfer J, Castaigne J P., Ondo A, Plassard A, Zohoun I. Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises. Agents Actions Suppl 1984 15 199-212
138. Zago M A., Costa F F., Ismael S J., Tone L G., Bottura C. Treatment of sickle cell diseases with aspirin. Acta Haematol 1984 72 1 61-64 (Pubitemid 14028625)
139. Mohan J S., Lip G Y., Wright J, Bareford D, Blann A D. Plasma levels of tissue factor and soluble E-selectin in sickle cell disease: relationship to genotype and to inflammation. Blood Coagul Fibrinolysis 2005 16 3 209-214 (Pubitemid 40547277)
140. Wood K, Russell J, Hebbel R P., Granger D N. Differential expression of E- and P-selectin in the microvasculature of sickle cell transgenic mice. Microcirculation 2004 11 4 377-385 (Pubitemid 39619087)
141. Blum A, Yeganeh S, Peleg A et al. Endothelial function in patients with sickle cell anemia during and after sickle cell crises. J Thromb Thrombolysis 2005 19 2 83-86 (Pubitemid 41131260)
142. Qari M H., Aljaouni S K., Alardawi M S. et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost 2007 98 2 392-396 (Pubitemid 47250243)
143. Ahmed S, Siddiqui A K., Iqbal U et al. Effect of low-dose warfarin on D-dimer levels during sickle cell vaso-occlusive crisis: a brief report. Eur J Haematol 2004 72 3 213-216 (Pubitemid 38250799)
144. Salvaggio J E., Arnold C A., Banov C H. Long-term anti-coagulation in sickle-cell disease. A clinical study. N Engl J Med 1963 269 182-186
145. Dobson S R., Holden K R., Nietert P J. et al. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood 2002 99 9 3144-3150 (Pubitemid 34525291)
146. Aessopos A, Farmakis D, Loukopoulos D. Elastic tissue abnormalities resembling pseudoxanthoma elasticum in beta thalassemia and the sickling syndromes. Blood 2002 99 1 30-35